Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.32)
# 1,023
Out of 4,914 analysts
205
Total ratings
48.33%
Success rate
2.42%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Reiterates: Neutral | $305 | $301.29 | +1.23% | 17 | Jun 24, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $535 | $460.83 | +16.09% | 3 | May 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $47.51 | +15.77% | 16 | Apr 23, 2025 | |
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $695 | $558.63 | +24.41% | 20 | Apr 22, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $24.31 | -1.28% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $35.87 | - | 1 | Apr 22, 2025 | |
| MRK Merck & Co. | Initiates: Neutral | $85 | $84.06 | +1.12% | 11 | Apr 22, 2025 | |
| LLY Eli Lilly and Company | Initiates: Overweight | $975 | $808.11 | +20.65% | 12 | Apr 22, 2025 | |
| GILD Gilead Sciences | Assumes: Overweight | $125 | $113.03 | +10.59% | 15 | Apr 22, 2025 | |
| ABBV AbbVie | Initiates: Overweight | $210 | $188.52 | +11.39% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $133.71 | +23.40% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $15.40 | +29.87% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $129.28 | +39.23% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $81.98 | +21.98% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $3 | $2.42 | +23.97% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $1.55 | +93.55% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.15 | +682.61% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $36.63 | +159.35% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $14.95 | +33.78% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $70.59 | +3.41% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.76 | +581.82% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $1.98 | -24.24% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.49 | +359.18% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $236.44 | +60.72% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $70.16 | +16.88% | 5 | Jan 16, 2019 |
Amgen
Jun 24, 2025
Reiterates: Neutral
Price Target: $305
Current: $301.29
Upside: +1.23%
Vertex Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: $535
Current: $460.83
Upside: +16.09%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $47.51
Upside: +15.77%
Regeneron Pharmaceuticals
Apr 22, 2025
Assumes: Overweight
Price Target: $695
Current: $558.63
Upside: +24.41%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $24.31
Upside: -1.28%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $35.87
Upside: -
Merck & Co.
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $84.06
Upside: +1.12%
Eli Lilly and Company
Apr 22, 2025
Initiates: Overweight
Price Target: $975
Current: $808.11
Upside: +20.65%
Gilead Sciences
Apr 22, 2025
Assumes: Overweight
Price Target: $125
Current: $113.03
Upside: +10.59%
AbbVie
Apr 22, 2025
Initiates: Overweight
Price Target: $210
Current: $188.52
Upside: +11.39%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $133.71
Upside: +23.40%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $15.40
Upside: +29.87%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $129.28
Upside: +39.23%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $81.98
Upside: +21.98%
Aug 14, 2024
Maintains: Overweight
Price Target: $10 → $3
Current: $2.42
Upside: +23.97%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $1.55
Upside: +93.55%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.15
Upside: +682.61%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $36.63
Upside: +159.35%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $14.95
Upside: +33.78%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $70.59
Upside: +3.41%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.76
Upside: +581.82%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $1.98
Upside: -24.24%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.49
Upside: +359.18%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $236.44
Upside: +60.72%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $70.16
Upside: +16.88%